Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Renal Cell Carcinoma
Advertisement
Latest News
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Drs. Joyce and Jani look toward the future of liquid biopsy in RCC care and how new technology, like AI, will play a role.
Drs. Joyce and Jani discuss practical clinical cases of using liquid biopsy to manage patients in different RCC settings.
Drs. Joyce and Jani talk about the technique of liquid biopsy and its role as a diagnostic tool in RCC.
The panel concludes with a candid discussion about the most urgent changes that could improve cancer care today.
The panel explores the importance of introducing palliative care discussions earlier in the treatment journey.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
![Monitoring [177Lu]Lu-PSMA Therapy in mCRPC: Clinical Protocols](https://mumcdnstorage.blob.core.windows.net/guonc/2022/09/Metastatic-prostate-cancer.jpg)
New research explores the prognostic potential of LuPSMA-SPECT/CT with RECIP 1.0 in patients with advanced prostate cancer.
Advertisement
Advertisement
Trending
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Drs. Joyce and Jani look toward the future of liquid biopsy in RCC care and how new technology, like AI, will play a role.
Drs. Joyce and Jani discuss practical clinical cases of using liquid biopsy to manage patients in different RCC settings.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.